Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HCC surveillance after SVR in patients with F3/F4 fibrosis
George N. Ioannou
Journal of Hepatology (2020) Vol. 74, Iss. 2, pp. 458-465
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
Georg Semmler, Elias Laurin Meyer, K Kozbial, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 812-821
Open Access | Times Cited: 105
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 86
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis
Ian Lockart, Malcolm Guan Hin Yeo, Behzad Hajarizadeh, et al.
Hepatology (2022) Vol. 76, Iss. 1, pp. 139-154
Open Access | Times Cited: 78
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 29
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung‐Wei Wang, Yi Zeng, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association (2025)
Open Access | Times Cited: 3
Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions
Hamish Innes, Pierre Nahon
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1332-1337
Open Access | Times Cited: 23
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients
Yu Jun Wong, Vincent Chen, Asim Abdulhamid, et al.
Hepatology (2024)
Closed Access | Times Cited: 10
Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
Ahmed Helmy
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
Nobuharu Tamaki, Masayuki Kurosaki
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 1
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease
Jérémy Dana, Aïna Venkatasamy, Antonio Saviano, et al.
Hepatology International (2022) Vol. 16, Iss. 3, pp. 509-522
Open Access | Times Cited: 34
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019
Masahito Nakano, Hiroshi Yatsuhashi, Shigemune Bekki, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Cristiane Valle Tovo, Ângelo Zambam de Mattos, Gabriela Perdomo Coral, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 2, pp. 343-356
Open Access | Times Cited: 18
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection
Chen‐Hua Liu, Pin‐Nan Cheng, Yu‐Jen Fang, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 8
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance
Nia Adeniji, Renumathy Dhanasekaran
Hepatology Communications (2021) Vol. 5, Iss. 12, pp. 1972-1986
Open Access | Times Cited: 40
The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
Jingjing Li, Chuanyong Guo, Jianye Wu
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 2619-2628
Open Access | Times Cited: 35
Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
Fang Huang, Chuan-Jing Dai, You-Ni Zhang, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 24
Inflammation and Digestive Cancer
Helge L. Waldum, Reidar Fossmark
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13503-13503
Open Access | Times Cited: 16
Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination
Jeffrey V. Lazarus, Camila A. Picchio, Massimo Colombo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14404-14404
Open Access | Times Cited: 14
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK
Victoria Hamill, Will Gelson, Douglas MacDonald, et al.
Liver International (2023) Vol. 43, Iss. 4, pp. 917-927
Open Access | Times Cited: 13
Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements
Abhilash Perisetti, Hemant Goyal, Rachana Yendala, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 24, pp. 3466-3482
Open Access | Times Cited: 28
Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study
Alessia Ciancio, Davide Giuseppe Ribaldone, Matteo Spertino, et al.
Biomedicines (2023) Vol. 11, Iss. 1, pp. 166-166
Open Access | Times Cited: 12
Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA‐II), serum a‐fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non‐diagnostic serum a‐fetoprotein levels
Antonia Syriha, Spyridon Pantzios, Dionysia Mandilara, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma
Jiacheng Liu, Yaowei Bai, Xiaoming Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma
Hua Dai, Tao Xin, Yongqian Shu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Long-term Survival Analysis after Radical Gastrectomy for Epstein-Barr Virus-Associated Gastric Cancer: A Multicenter Study
Rong-Zhen Xie, Ze‐Ning Huang, Xingqi Zhang, et al.
European Journal of Surgical Oncology (2025), pp. 109737-109737
Closed Access
Page 1 - Next Page

Scroll to top